• Tuesday, March 10, 2020 @ 12:00 am

Santersus AG has initiated its second Porcine model with a further 20 subjects. This is now an extension of the first preclinical trial to further analyse the efficacy of the technology in relation to treating sepsis in the previous E.coli 7 hour model.
“With the extremely positive results we saw in the first study, we feel the larger second porcine preclinical model should solidify our technology’s initial purpose in meeting an unmet clinical need relating to sepsis moving forward”.